SCHEMBL20913913

SCHEMBL20913913

COc1cccc2oc(-c3c(C)[nH]c4c(-c5cccc(F)c5)c(C#N)nn4c3=O)nc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNA5 P22460 3/20 0.38
▸ KCNH2 Q12809 3/20 0.38
▸ PSEN1 P49768 1/20 0.36
▸ PSEN2 P49810 1/20 0.36
▸ APH1B Q8WW43 1/20 0.36
▸ NCSTN Q92542 1/20 0.36
▸ APH1A Q96BI3 1/20 0.36
▸ PSENEN Q9NZ42 1/20 0.36
▸ TNKS O95271 1/20 0.33
▸ TNKS2 Q9H2K2 1/20 0.33
▸ PARP2 Q9UGN5 1/20 0.33
▸ F2RL3 Q96RI0 2/20 0.33
▸ UTRN P46939 1/20 0.33
▸ AR P10275 1/20 0.32
▸ CXCR2 P25025 1/20 0.32
▸ CTSA P10619 1/20 0.32
▸ KDM4E B2RXH2 3/20 0.32
▸ ALDH1A1 P00352 3/20 0.32
▸ HPGD P15428 3/20 0.32
▸ HSD17B10 Q99714 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914077 0.91 TNKS (0.37) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL20914067 0.86 ARF6 (0.35) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL20837249 0.83 TNKS (0.37) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL20914035 0.82 MAT2A (0.34) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL20914059 0.82 MAT2A (0.33) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL20914160 0.82 TNKS (0.35) TNKSTNKS2PARP2F2RL3AR
SCHEMBL20914221 0.81 HTR3A (0.31) —
SCHEMBL20914030 0.81 PSEN1 (0.35) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL20836948 0.81 TNKS (0.35) TNKSTNKS2PARP2F2RL3KDM4E
SCHEMBL20931219 0.80 TNKS (0.40) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 KCNA5 1138/4885KCNH2 770/4885PSEN1 146/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 KCNA5 1138/4885KCNH2 770/4885PSEN1 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback